Supriya Lifescience Ltd (SUPRIYA) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a strong 31% year-on-year revenue growth, demonstrating robust underlying demand for its products.
- EBITDA margins were temporarily impacted, declining to 25%, primarily due to a combination of external, one-off factors including a regional water shortage and changes in the state's solar power policy.
- Despite quarterly headwinds, management reiterated its full-year guidance, remaining confident in achieving the INR 1,000 crore revenue milestone for FY27 with EBITDA margins in the 32-35% range.
- The company is making significant progress on its strategic initiatives, including the development of the new Pathalganga facility, new product launches, and advancing CMO/CDMO collaborations.
- Exports continue to be the primary growth engine, contributing 81% of total revenue, with strong performance in key markets like Asia and Europe.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.